These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 26731686

  • 1. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 3. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
    Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J, VVA Prasterone Group.
    Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
    [Abstract] [Full Text] [Related]

  • 4. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group.
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [Abstract] [Full Text] [Related]

  • 5. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
    Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M.
    Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
    [Abstract] [Full Text] [Related]

  • 6. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
    Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi É, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Côté I, Lavoie L, Martel C, Balser J, VVA Prasterone Group.
    Climacteric; 2015 Nov; 18(4):590-607. PubMed ID: 25511551
    [Abstract] [Full Text] [Related]

  • 7. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
    Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É, Members of the VVA Prasterone Group.
    Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
    [Abstract] [Full Text] [Related]

  • 8. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH.
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [Abstract] [Full Text] [Related]

  • 9. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
    Archer DF, Labrie F, Montesino M, Martel C.
    J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
    [Abstract] [Full Text] [Related]

  • 10. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J.
    J Sex Med; 2014 Jul; 11(7):1766-85. PubMed ID: 24774442
    [Abstract] [Full Text] [Related]

  • 11. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
    Portman DJ, Goldstein SR, Kagan R.
    Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
    [Abstract] [Full Text] [Related]

  • 12. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Feb; 16(5):907-22. PubMed ID: 19436225
    [Abstract] [Full Text] [Related]

  • 13. Prasterone: A Review in Vulvovaginal Atrophy.
    Heo YA.
    Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
    [Abstract] [Full Text] [Related]

  • 14. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
    Wang J, Wang L.
    Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
    [Abstract] [Full Text] [Related]

  • 15. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D, Palacios S, Nappi RE, Mueck AO.
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [Abstract] [Full Text] [Related]

  • 16. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
    Archer DF.
    J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F, Caruso S, Di Lorenzo G, Romano F, Mirandola M, Nappi RE.
    Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
    [Abstract] [Full Text] [Related]

  • 18. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
    Labrie F, Montesino M, Archer DF, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    Climacteric; 2015 May; 18(6):817-25. PubMed ID: 26517756
    [Abstract] [Full Text] [Related]

  • 19. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
    Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, Gasper G, Graham S, Mirkin S, REJOICE Study Group.
    Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
    [Abstract] [Full Text] [Related]

  • 20. Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient?
    Kearley-Shiers K, Holloway D, Janice Rymer, Bruce D.
    Post Reprod Health; 2022 Dec; 28(4):237-243. PubMed ID: 36300276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.